Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index ... , in particular, drug/device combinations. The current system received a score of 0 (range ... Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material in ... Although there are a considerable number of terms in popular use to describe it, ... is a mixture of mucus, blood cells, skin cells and dust, but until now ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee ... to protect the Orange County, Texas area from future storm surge flooding, such as ... determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic and ...
(Date:7/29/2015)... ... July 29, 2015 , ... Nearly everyone has heard of ... few people realize that a rich source of these cells is teeth—baby teeth that ... that need to be pulled to make room for braces. These potent stem ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2
... Hong Kong-based subsidiary Pangu BioPharmaSAN DIEGO, March 10 ... discovery and development of an entirely new class of ... announced that Dr. James Cai has joined the Company ... Pharma and President of Pangu BioPharma, a fully owned ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; ... the 29th Annual Cowen and Company Health Care Conference ... a.m. Eastern Time.A live webcast of the presentation can ... http://investor.zimmer.com . The webcast will be archived for ...
... Reduce the Risks of DVT to Mark U.S. House ... The Coalition to Prevent DVT today announced the launch ... about deep-vein thrombosis (DVT) and to encourage dialogue between ... condition. A customized recreational vehicle will visit hospitals ...
Cached Biology Technology:Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 2Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 3The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 2The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 3The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 4The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 5
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Could straw houses be the buildings of the future? ... testing this summer by constructing a "BaleHaus" made of prefabricated ... And people around the world will be able to watch ... www.bath.ac.uk/features/balehaus/ ,- part of a site which will also ...
... Fla. (July 27, 2009) An Italian research team, ... (18:4), which is now available on-line without charge ... derived from human placenta may ultimately play a role ... fibrosis and fibrotic diseases caused by tuberculosis, chemical exposure, ...
... Ph.D., from the Louisiana Universities Marine Consortium (LUMCON), found the ... be smaller than forecasted, measuring 3,000 square miles. However the ... the sea floor, was severe where it did occur, extending ... Earlier this summer, NOAA-sponsored forecast models developed by R. ...
Cached Biology News:University has grand designs to build a house of straw 2University has grand designs to build a house of straw 3Placenta-derived stem cells may help sufferers of lung diseases 2Smaller than expected, but severe, dead zone in Gulf of Mexico 2
... Application: The simple three step procedure (PCR, ... be completed in one day. The typical ... than 80%. , Features and Benefits: , ... cloned into any expression vector , High ...
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,667-7) ... assistance. ID clarifier: barcoded, bulk ...
Biology Products: